19 completed, 2 unknown, 2 withdrawn, 1 not yet recruiting. 26 Phase 2, 7 Phase 1, 1 Phase 3.
Follow AIDS: new trials by email Literature Review of AIDS trials Research Report on AIDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Sintilimab - HIV, AIDS | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Public Health Clinical Center | 50 | 2026-05-01 | 2026-05-12 |
| Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage mesenchymal stem cell, saline - AIDS | Phase 1 / Phase 2 | Recruiting | Cell Energy Life Sciences Group Co. LTD | 150 | 2023-12-10 | 2025-08-12 |
| Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women Cannabis, Placebo - HIV, AIDS | Phase 2 | Completed | Albert Einstein College of Medicine | 25 | 2020-10-23 | 2025-10-15 |
| Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients single dose of L-AmB, 2 doses of L-AmB, 2 weeks of L-AmB - Histoplasmosis, AIDS | Phase 2 | Completed | Alessandro Pasqualotto | 118 | 2020-02-14 | 2025-03-14 |
| N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV N-803 and bNAbs, haNK™ Cells - Hiv, HIV/AIDS | Phase 1 / Phase 2 | Withdrawn | University of Minnesota | 2020-01-01 | 2020-10-22 | |
| Treatment of PD-1 Inhibitor in AIDS-associated PML Pembrolizumab - Progressive Multifocal Leukoencephalopathy, AIDS | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 10 | 2019-08-20 | 2019-09-20 |
| A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF. - AIDS | Phase 2 | Completed | Henan Genuine Biotech Co., Ltd. | 172 | 2017-10-10 | 2019-09-30 |
| A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin - Kaposi's Sarcoma, HIV Positive | Phase 2 | Completed | ImmunityBio, Inc. | 15 | 2014-04-03 | 2024-06-11 |
| Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults Ad35-GRIN, MVA.HIVconsv, pSG2.HIVconsv DNA - AIDS | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2014-03-01 | 2016-05-30 |
| Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein Tat Oyi - AIDS | Phase 1 / Phase 2 | Unknown | BIOSANTECH | 50 | 2013-02-01 | 2016-02-10 |
| Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) DNA vaccine, DNA vaccine prime with the addition of electroporation, rTV boost - AIDS | Phase 2 | Completed | National Center for AIDS/STD Control and Prevention, China CDC | 150 | 2012-08-01 | 2015-05-06 |
| Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Extended-Release Naltrexone - HIV, AIDS | Phase 1 / Phase 2 | Completed | Yale University | 151 | 2011-03-01 | 2020-03-19 |
| Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons GSK Biologicals HIV Vaccine 732462, Placebo - AIDS | Phase 2 | Completed | GlaxoSmithKline | 191 | 2010-11-08 | 2018-05-21 |
| HIV/AIDS, Severe Mental Illness and Homelessness Skills Building - Motivational Interviewing - HIV, AIDS | Phase 2 | Completed | Boston Medical Center | 240 | 2010-10-01 | 2016-04-01 |
| Study Targeting Affect Regulation Resilient Affective Processing Therapy (RAPT) - HIV, AIDS | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 56 | 2010-09-01 | 2014-10-27 |
| Vitamin D Dose Finding Study Cholecalciferol (Vit D3) - HIV Infections, AIDS | Phase 2 | Completed | Children's Hospital of Philadelphia | 44 | 2010-01-01 | 2013-09-18 |
| Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose GSK Biologicals' HIV vaccine (732461), Chloroquine - AIDS | Phase 2 | Completed | GlaxoSmithKline | 28 | 2009-12-01 | 2018-08-17 |
| Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy dimiracetam, sugar pill - Neuropathy, AIDS | Phase 2 | Completed | Neurotune AG | 116 | 2009-10-01 | 2010-06-02 |
| HIV Prevention for Injecting Drug Users in Kazakhstan Couples Based HIV/STI Risk Reduction Intervention (CHSR), Renaissance Wellness Promotion (WP) - HIV, AIDS | Phase 2 | Completed | Columbia University | 600 | 2008-05-01 | 2014-02-27 |
| Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Nevirapine based therapy, Efavirenz based therapy, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) - Tuberculosis, Aids | Phase 2 / Phase 3 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 570 | 2007-12-01 | 2012-02-15 |
Showing 20 of 26. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (26) · HIV Infections (8) · Substance-Related Disorders (2) · Fatigue (1) · HIV Seropositivity (1) · Histoplasmosis (1) · Infections (1) · Leukoencephalopathy, Progressive Multifocal (1) · Neoplasms (1) · Neuralgia (1) · Opioid-Related Disorders (1) · Opportunistic Infections (1) · Sarcoma (1) · Sarcoma, Kaposi (1) · Systemic carnitine deficiency (1)
Blood-Borne Infections (26) · Communicable Diseases (26) · Genital Diseases (26) · Immune System Diseases (26) · Immunologic Deficiency Syndromes (26) · Lentivirus Infections (26) · RNA Virus Infections (26) · Retroviridae Infections (26) · Sexually Transmitted Diseases (26) · Sexually Transmitted Diseases, Viral (26) · Slow Virus Diseases (26) · Urogenital Diseases (26) · Virus Diseases (26) · Infections (25) · HIV Infections (18)
ALT-803 (1) · Broadly Neutralizing Antibodies (1) · Carnitine (1) · Chloroquine (1) · Cholecalciferol (1) · Didanosine (1) · Ethambutol (1) · Immune Checkpoint Inhibitors (1) · Isoniazid (1) · Lamivudine (1) · Naltrexone (1) · Protons (1) · Pyrazinamide (1) · Rifampin (1) · Sodium Chloride (1)
GlaxoSmithKline (3) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Albert Einstein College of Medicine (1) · Alessandro Pasqualotto (1) · BIOSANTECH (1) · Boston Medical Center (1) · Cell Energy Life Sciences Group Co. LTD (1) · Children's Hospital of Philadelphia (1) · Columbia University (1) · Designed Altobaric Technology, Incorporated (1) · First Affiliated Hospital of Zhejiang University (1) · Henan Genuine Biotech Co., Ltd. (1) · ImmunityBio, Inc. (1) · Merck Sharp & Dohme LLC (1) · National Center for AIDS/STD Control and Prevention, China CDC (1)
United States (11) · China (5) · Belgium (2) · France (2) · Brazil (1) · Burkina Faso (1) · Germany (1) · Kazakhstan (1) · Kenya (1) · Mozambique (1) · South Africa (1) · Spain (1)
Aboubacar Nacro, MD (1) · Adam Carrico, PhD (1) · Anjali Sharma, MD, MS (1) · Bei-Hung Chang, Sc.D (1) · Biao Zhu, PhD (1) · Daiane Dalla Lana, PhD (1) · Daniel R Malan, MD (1) · Frederick L Altice (1) · Fu-Sheng Wang, Doctor (1) · Hao Wu, M.D. (1) · Isabelle Ravaux, MD (1) · Jori Berger-Greenstein, PhD (1) · Maryline Bonnet, MD (1)
PMID 24391139, PMID 20516271, PMID 21208909, PMID 21300566, PMID 21343146, PMID 21857286, PMID 21860356, PMID 22561365, PMID 23059649, PMID 23433590, PMID 23719348, PMID 23878319, PMID 24663014, PMID 24674234, PMID 26560326, PMID 26625449, PMID 29373393, PMID 40342086
K02DA032322 (1), R01AT005531 (1), R21AG059505 (1)